The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.
Facts tucked among the 9.2 million lines of data: 2% of doctors account for around 25% of Medicare billing.
The regulator has put off the inhaled insulin's PDUFA date by three months.
The ACA has spurred double-digit increases in demand for pharmaceuticals, new data suggest.
The FDA has issued draft guidance that funds FDA inspection of some drug compounders.
At a hearing today, Public Citizen and the generics industry are sounding off on an FDA proposal that would allow generics firms to update labels, regardless of whether the brand has or hasn't.
The Bay State is saying no to the controversial prescription painkiller.
Longtime industry critic, Congressmen Henry Waxman penned a note to Gilead CEO over the "extraordinarily high cost," of its recently approved HCV treatment Sovaldi.
A rival's late-stage trial results suggest the pain med may have a short market life. The key: an FDA division head's documented willingness to overturn the approval should another pain option surface.
Around 25% of 18-34 year-olds have signed up for coverage. Obama's FunnyorDie appearance drives HHS traffic.